BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production
BOSTON, February 7, 2023 /PRNewswire/ -- BrickBio Highlights Unique Advantages from the Proprietary "VADER" System, published on Dec 22,...
top of page
ENHANCING AN
ANCIENT MOLECULE
FOR MODERN DAY THERAPEUTICS
Rewriting the Genetic Blueprint:
Best-In-Class Therapeutics Unlocked with
Synthetic Amino Acids
Delivering on the promise of antibody-conjugates and protein therapeutics
BrickBio's industry-leading technology empowers the precise customization of proteins to develop unrivaled biologics with an unprecedented therapeutic window for improved patient outcomes. The core technology enables first-in-class mammalian expression platforms using evolved versions of ancient tRNA molecules for homogenous, site-specific incorporation of synthetic amino acid conjugation handles into novel, optimized sites in any protein backbone.
HomePage Tec
Therapeutics have relied on suboptimal conjugation methods, resulting in a staggering number of failed therapeutics due to heterogeneity, lack of stability, or lack of precise control of the conjugation site.
ETRNAL Platform
The Evolved tRNA Localization Platform solves these limitations
Optimal Conjugation Sites for Best-in-Class Molecules
BrickBio Identifies Stable Conjugation Sites to
Shield ADC Payloads and Optimize their Activity
-
BrickBio mammalian expression systems enable efficient synthetic amino acid (conjugation handle) incorporation at any site within a protein backbone
-
The Evolved tRNA Localization (ETRNAL) Platform enables 10x more efficient machinery for synthetic amino acid incorporation and more diverse, efficient chemistries
-
Existing conjugation technologies with unstable and limited sites lead to poor clinical outcomes
-
Stable sites with BrickBio chemistry can shield undesired properties (i.e. toxicity)
-
Previously inaccessible sites enable unprecedented biophysical characteristics
Translates to Safer, More Efficacious Therapeutics
BrickBio ADCs are 5x safer and more efficacious than
other conjugation strategies with the same linker-payload
-
BrickADC therapeutic index outcompetes cysteine, other site-specific conjugation technologies, and FDA approved ADCs.
-
Improvements derived from: Stable Conjugation, Reduced Hydrophobicity, Tuned Exposure, Lower Hydrodynamic Radius, Optimized Cleavage Kinetics, Additional Biophysical Optimization
High-Throughput Site Prediction for Any Payload
Site-Selection Panel Algorithm is Driven by Thousands
of Empirical and Literature-Backed Data Points for Any Payload Structure
-
Wet-lab data for all BrickADCs and literature data are compiled into proprietary data set
-
New or existing payload structures can be analyzed for optimal conjugation sites in silico (see above) and rapidly tested in vitro/in vivo
-
Reproducible prediction demonstrated with partnered and internal assets
Expand the ADC Status Quo: Multi-Payload Conjugates
Combine multiple distinct payloads with synergistic mechanisms of action
for unprecedented patient outcomes
-
Multi-payload conjugation is performed in a one-pot reaction providing a simplified CMC process
-
First-in-Class stable CHO cell line for commercial scalability
-
Addresses unmet need: payload resistance, low efficacy, incomplete cancer immunity cycle
TECH
Pipeline Snapshot
Pipeline
RECENT NEWS
RECENT NEWS
Management Team
CEO, CO-FOUNDER,
TIGER GENE
VP, COMMERCIAL
DEVELOPMENT
SENIOR ADVISOR &
CHAIRMAN OF SAB
HEAD OF BUSINESS DEVELOPMENT
CHIEF SCIENTIFIC
OFFICER
OUR TEAM
Careers
Join our team!
At BrickBio, our highly collaborative team drives to make an impact in patient's lives through our revolutionary platform technologies. We're looking for determined leaders in biotech who are passionate, innovative, and want to set the bar high for the next generation of protein therapeutics.
Careers
CONTACT
BRICKBIO
OUR ADDRESS
600 Winter Street
Waltham, MA, 02451, USA
For any general inquiries, please fill in the following contact form:
contact
bottom of page